Literature DB >> 15481321

Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats.

György Rumi1, Ryouichi Tsubouchi, Mitsuaki Okayama, Shinichi Kato, Gyula Mózsik, Koji Takeuchi.   

Abstract

Promising results have recently been obtained with pre- and probiotic therapy in ulcerative colitis (UC). The prebiotic potential of lactulose is well established, but it has not yet been investigated in experimental colitis models. The purpose of the study was to examine the effect of lactulose on an UC model induced by 3% dextran sulfate sodium (DSS) solution added to drinking water for 7 days in male Wistar rats. Lactulose (300-1000 mg/kg) or 5-aminosalicylic acid (5-ASA; 150 mg/kg) was administered orally twice daily for 6 days. Colonic ulceration area, colon length, body weight changes, diarrhea/bloody feces, colonic mucosal myeloperoxidase activity (MPO), thiobarbituric acid reactive substances (TBARS), and histology were examined. Treatment of animals with DSS for 7 days resulted in severe colonic lesions accompanied by diarrhea, bloody feces, a decrese in body weight, shortening of the colon length, and an increase in MPO activity as well as TBARS, compared to normal rats. Lactulose treatment ameliorated DSS-induced colitis in a dose-dependent manner, and at 1000 mg/kg all of the parameters examined, except TBARS, were shown to improve significantly as compared to controls. Daily administration of 5-ASA also significantly reduced the severity of colonic lesions following DSS treatment. These results demonstrated the protective effect of lactulose in this rat colitis model and suggested that the background of this lactulose effect may be due to alterations of colonic microflora.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15481321     DOI: 10.1023/b:ddas.0000042248.48819.ad

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

Review 1.  Medical, nutritional and technological properties of lactulose. An update.

Authors:  Christian Schumann
Journal:  Eur J Nutr       Date:  2002-11       Impact factor: 5.614

2.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function.

Authors:  K Madsen; A Cornish; P Soper; C McKaigney; H Jijon; C Yachimec; J Doyle; L Jewell; C De Simone
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

3.  Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment.

Authors:  S Ulisse; P Gionchetti; S D'Alò; F P Russo; I Pesce; G Ricci; F Rizzello; U Helwig; M G Cifone; M Campieri; C De Simone
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

Review 4.  Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.

Authors:  R B Sartor
Journal:  Gastroenterol Clin North Am       Date:  1995-09       Impact factor: 3.806

5.  Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment.

Authors:  Osamu Kanauchi; Isao Serizawa; Yoshio Araki; Asuka Suzuki; Akira Andoh; Yoshihide Fujiyama; Keiichi Mitsuyama; Kosuke Takaki; Atsushi Toyonaga; Michio Sata; Tadao Bamba
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

6.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

7.  Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission.

Authors:  Andrew Szilagyi; Julie Rivard; Ian Shrier
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

8.  Treatment of ulcerative colitis using fecal bacteriotherapy.

Authors:  Thomas J Borody; Eloise F Warren; Sharyn Leis; Rosa Surace; Ori Ashman
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

9.  Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis.

Authors:  Hideki Ishikawa; Ikuko Akedo; Yoshinori Umesaki; Ryuichiro Tanaka; Akemi Imaoka; Toru Otani
Journal:  J Am Coll Nutr       Date:  2003-02       Impact factor: 3.169

10.  The rectal mucosa-associated microflora in patients with ulcerative colitis.

Authors:  M G Hartley; M J Hudson; E T Swarbrick; M J Hill; A E Gent; M D Hellier; R H Grace
Journal:  J Med Microbiol       Date:  1992-02       Impact factor: 2.472

View more
  19 in total

Review 1.  Probiotics and prebiotics in chronic inflammatory bowel diseases.

Authors:  Julia B Ewaschuk; Levinus A Dieleman
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

Review 2.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 3.  Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity.

Authors:  Jessica Soldavini; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2013-07-10       Impact factor: 3.199

4.  Positive role of CCAAT/enhancer-binding protein homologous protein, a transcription factor involved in the endoplasmic reticulum stress response in the development of colitis.

Authors:  Takushi Namba; Ken-Ichiro Tanaka; Yosuke Ito; Tomoaki Ishihara; Tatsuya Hoshino; Tomomi Gotoh; Motoyoshi Endo; Keizo Sato; Tohru Mizushima
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

Review 5.  The interplay between fiber and the intestinal microbiome in the inflammatory response.

Authors:  Shiu-Ming Kuo
Journal:  Adv Nutr       Date:  2013-01-01       Impact factor: 8.701

6.  Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease.

Authors:  Sofia Tedelind; Fredrik Westberg; Martin Kjerrulf; Alexander Vidal
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

Review 7.  Prebiotics in chronic intestinal inflammation.

Authors:  Mirjam A C Looijer-van Langen; Levinus A Dieleman
Journal:  Inflamm Bowel Dis       Date:  2009-03       Impact factor: 5.325

8.  Diet and Inflammatory Bowel Disease.

Authors:  Karina Knight-Sepulveda; Susan Kais; Rebeca Santaolalla; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-08

9.  Drinking hydrogen water and intermittent hydrogen gas exposure, but not lactulose or continuous hydrogen gas exposure, prevent 6-hydorxydopamine-induced Parkinson's disease in rats.

Authors:  Mikako Ito; Masaaki Hirayama; Kazuaki Yamai; Sae Goto; Masafumi Ito; Masatoshi Ichihara; Kinji Ohno
Journal:  Med Gas Res       Date:  2012-05-20

10.  Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases.

Authors:  D Ortuño Sahagún; A L Márquez-Aguirre; S Quintero-Fabián; R I López-Roa; A E Rojas-Mayorquín
Journal:  PPAR Res       Date:  2012-11-28       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.